See the DrugPatentWatch profile for cosentyx

Based on the information provided, there is no specific data on how Cosentyx (secukinumab) interacts with live or inactivated vaccines. However, it is generally recommended to avoid live vaccines during biologic therapy, including Cosentyx, due to the potential risk of infection.

Cosentyx is a human monoclonal antibody that specifically binds to interleukin-17A (IL-17A), a naturally occurring cytokine in the body, and inhibits its interaction with the IL-17 receptor. By blocking the activity of IL-17A, Cosentyx helps reduce inflammation and symptoms of certain autoimmune diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

According to the Cosentyx Prescribing Information, "the safety of Cosentyx in patients with a history of live vaccination has not been established" [1]. Furthermore, the FDA-approved label for Cosentyx states that "vaccination with live vaccines is not recommended in patients receiving Cosentyx" [1].

Therefore, while there is no specific information on how Cosentyx interacts with live or inactivated vaccines, it is generally advised to avoid live vaccines during treatment with Cosentyx due to the potential risks associated with biologic therapy.

Sources:
[1] Cosentyx (secukinumab) Prescribing Information. Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.